Form 6-K FSD Pharma Inc. For: Dec 03
|
FSD Pharma Inc.
|
|
|
(Registrant)
|
|
Date: December 3, 2021
|
By: |
/s/ Nathan Coyle
|
|
Nathan Coyle, Chief Financial Officer
|
Exhibit
|
Description
|
99.1 |
Press Release – Dated December 3, 2021 - FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th |
Exhibit 99.1 |
FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
TORONTO--(BUSINESS WIRE)--December 3, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright 2nd Annual Virtual Psychedelics Conference to be held on December 6, 2021. Mr. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET and accessible to view on the investor relations section of FSD’s website at https://ir.fsdpharma.com/news-events/events-presentations.
In addition, members of FSD Pharma’s management team will be available for one-on-one investor meetings during the conference.
For more information about the conference, or to schedule a one-on-one meeting with FSD's management team, please contact KCSA Strategic Communications at [email protected] or an H.C. Wainwright representative directly.
About FSD Pharma
FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. (“FSD BioSciences”) is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Through the Company’s wholly owned subsidiary, Lucid, the Company is also focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.
Contacts
Zeeshan Saeed, President, Founder and Director, FSD Pharma Inc.
Email: [email protected]
Telephone: (416) 854-8888
Investor Relations: Email: [email protected], Website: www.fsdpharma.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FSD Pharma Inc. (HUGE) Signs the Agreement With iNGENu CRO to Conduct a Trial of Lucid-21-302
- FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
- Building Your Credit: Applying for Credit Cards Online Responsibly
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!